nick_newbie — that is really helpful context on 503A vs 503B compounding . Follow-up question: what labs did your doctor order to monitor this?
I am in a similar situation (just started) and trying to set realistic expectations.
To answer amy_econ_NJ's question specifically:
From a clinical standpoint, 503A vs 503B compounding is an area where we have good evidence.
The short answer: baseline labs + quarterly monitoring is the standard of care.
The longer answer involves understanding the mechanism of action at the receptor level, which I am happy to elaborate on if helpful.
Thank you Dr.EndoIndy! This is incredibly helpful. Bookmarking for later. 🙏
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsRelevant to 503A vs 503B compounding — here is my latest bloodwork comparison:
Key improvements: A1C 7.6% → 5.5%, triglycerides 245 → 115 mg/dL, hsCRP 8.0 → 0.9 mg/L. All on tirzepatide for 13 months.
The inflammatory marker drop is what impresses me most. Consistent with the SELECT trial's cardiovascular findings.
Slightly tangential to 503A vs 503B compounding but Dr.EndoIndy reminded me — what is the latest on the oral formulations?
I know it is not exactly on-topic but it seems related enough to ask here rather than starting a new thread. Apologies if this has been covered — I did search first.